Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 4mg Dexamethasone Clear all
Withdrawn Phase 2 Interventional

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 7, 2026, 5:18 PM EDT
Withdrawn Not applicable Interventional

Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg

NCT01641419
View directory record Official record
Conditions
Pain, Sciatic Block
Interventions
Placebo, Dexamethasone 4 mg, Dexamethasone 8 mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

NCT02525718
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Early Phase 1 Interventional

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

NCT01861340
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, and MEDI-551
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery

NCT03822182
View directory record Official record
Conditions
Rotator Cuff Tear, Pain, Postoperative
Interventions
liposomal bupivicaine, Dexamethasone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Avon, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine vs Dexamethasone ISB

NCT04047446
View directory record Official record
Conditions
Shoulder Pain
Interventions
Exparel 133 MG Per 10 ML Injection, Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 7, 2026, 5:18 PM EDT
Active, not recruiting Phase 2 Interventional

Ixazomib Maintenance Study in Patients With AL Amyloidosis

NCT03618537
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 7, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure

NCT07216820
View directory record Official record
Conditions
Shoulder Surgery, Obesity
Interventions
Ultrasound-Guided Interscalene Brachial Plexus Block, Phrenic-Sparing Block Combination (Experimental), Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone 4mg
Procedure · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 7, 2026, 5:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma

NCT02111785
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Dexamethasone, Burr Hole Craniostomy
Drug · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 7, 2026, 5:18 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 7, 2026, 5:18 PM EDT
Recruiting Phase 2 Interventional

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

NCT02393157
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Interventions
Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 31 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

NCT01570387
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Pomalidomide, Dexamethasone
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 7, 2026, 5:18 PM EDT
Not listed Phase 1Phase 2 Interventional Results available

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

NCT01754402
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Cristina Gasparetto
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 7, 2026, 5:18 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Low Dose Dexamethasone for Distal Radius Fractures

NCT05274113
View directory record Official record
Conditions
Post Operative Pain, Distal Radius Fracture
Interventions
Dexamethasone 4mg, Ropivacaine
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 7, 2026, 5:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 7, 2026, 5:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

NCT07099222
View directory record Official record
Conditions
Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions
Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

NCT03040011
View directory record Official record
Conditions
Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions
Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline
Drug · Procedure
Lead sponsor
Lauren Giugale, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 7, 2026, 5:18 PM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433
View directory record Official record
Conditions
DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 7, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

NCT01736917
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Fosaprepitant, Dexamethasone, 5HT3
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
15 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • St Louis, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Sep 7, 2026, 5:18 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean Delivery

NCT03877549
View directory record Official record
Conditions
Post Operative Pain
Interventions
Dexamethasone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 7, 2026, 5:18 PM EDT
Not listed Phase 1Phase 2 Interventional

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04942067
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
APG-2575+ Pd, APG-2575 + DRd
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 7, 2026, 5:18 PM EDT
Completed No phase listed Interventional Results available

Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone

NCT03969875
View directory record Official record
Conditions
Total Shoulder Arthroplasty, Shoulder Osteoarthritis
Interventions
Interscalene catheter, Liposomal bupivacaine, Dexamethasone, Bupivacaine
Device · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 7, 2026, 5:18 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 5:18 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery

NCT03183596
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine, Dexamethasone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 7, 2026, 5:18 PM EDT